Urticaria
Find comprehensive information on urticaria, including hives, wheals, angioedema, and chronic idiopathic urticaria. This resource covers clinical documentation, ICD-10 codes (L50), medical coding, diagnosis, treatment, and management of urticaria for healthcare professionals. Learn about allergy testing, dermatology referrals, and the different types of urticaria, from acute to chronic. Explore effective treatment options and best practices for documenting urticaria in medical records.
Hives: raised, itchy skin welts due to allergic reaction.
Red, itchy wheals (bumps), swelling, sometimes angioedema.
Exposure to allergens (foods, medications, insect stings).
ICD-10 Code Families
Complete code families applicable to L50.9
When to use each related code
| Description | When to use |
|---|---|
| Hives; raised itchy bumps | Acute or chronic raised, itchy wheals. Consider triggers like allergens, medications. |
| Angioedema; swelling beneath skin | Swelling of deeper skin layers, often face, lips, tongue. May accompany urticaria. Code both if present. |
| Atopic dermatitis; eczema | Chronic itchy rash, dry skin, often flexural surfaces. Distinct from urticaria's transient wheals. |
Best-practice checklist
- ✓Urticaria diagnosis documented
- ✓Hives onset, duration, triggers noted
- ✓Distribution, morphology of wheals described
- ✓Associated symptoms pruritus, angioedema
- ✓ICD-10-CM L50.9 or appropriate subtype coded
Common pitfalls to avoid
Coding L50.9 (Urticaria, unspecified) without sufficient documentation specifying the type or cause can lead to claim denials and inaccurate quality reporting.
Miscoding allergic urticaria (L50.0-L50.4) as non-allergic or vice-versa impacts reimbursement and may trigger audits due to differing clinical severity.
Incorrectly documenting and coding chronic urticaria (L50.8) instead of acute or specific types can lead to under-coding and lost revenue.
Best-practice tips
- 01Document urticaria triggers (ICD-10-CM C14.9, L50.9) for accurate coding.
- 02Detailed HPI improves CDI for chronic urticaria (L50.8). Specify duration, morphology.
- 03Rule out angioedema (T78.3). Clearly document to ensure compliant billing.
- 04For physical urticaria, document eliciting factor (e.g., dermographism, cold).
- 05Review medications. Drug-induced urticaria (L50.0) requires specific documentation.
Step-by-step checklist
- 1
Verify acute vs chronic: <4 or >6 weeks?
- 2
Document wheal morphology, distribution, and pruritus
- 3
Assess angioedema: lip, eyelid, or genital swelling
- 4
Rule out other dermatoses: eczema, bullous pemphigoid
- 5
Consider triggers: food, meds, insect bites, infection
Ready-to-paste narrative
Subjective: Patient presents with complaints of hives (urticaria), describing pruritic, raised, erythematous wheals of varying sizes. Onset of symptoms reported as [Timeframe - e.g., two days ago, several hours ago]. Patient denies fever, chills, or shortness of breath. Associated symptoms may include angioedema, itching (pruritus), and dermatographism. Patient reports [Triggers if known - e.g., recent medication change, new food ingestion, insect bite, stress]. Review of systems otherwise negative. Past medical history includes [Relevant medical history - e.g., eczema, asthma, allergies]. Current medications include [List medications]. Allergies include [List allergies]. Objective: Physical examination reveals multiple well-circumscribed, raised, erythematous wheals distributed on [Location - e.g., trunk, extremities, face]. Individual lesions range in size from [Size - e.g., a few millimeters to several centimeters]. No evidence of airway compromise or angioedema noted. Dermatographism [Positive or negative]. Vital signs stable. Heart, lung, and abdominal examinations unremarkable. Assessment: Diagnosis of acute urticaria is made based on the characteristic clinical presentation and history. Differential diagnoses considered include allergic reaction, drug eruption, and viral exanthem. Severity assessed as [Mild, moderate, or severe] based on symptom distribution, pruritus intensity, and presence or absence of systemic symptoms. Plan: Patient educated on the nature of urticaria, potential triggers, and management strategies. Recommended treatment includes [Treatment plan - e.g., oral antihistamines (H1 blockers like cetirizine or diphenhydramine), H2 blockers (like ranitidine or famotidine if indicated), short course of oral corticosteroids if severe, avoidance of identified triggers]. Patient advised to return for follow-up if symptoms worsen or do not resolve within [Timeframe - e.g., one week]. ICD-10 code L50.9 (Urticaria, unspecified) is assigned. Patient provided with information regarding anaphylaxis symptoms and emergency contact information. Emphasis placed on trigger avoidance and symptom management.
Common questions and answers
What are the most effective diagnostic approaches for chronic spontaneous urticaria in adults, considering both first-line and second-line testing strategies?+
Diagnosing chronic spontaneous urticaria (CSU) in adults primarily relies on a thorough clinical history and physical examination focusing on the characteristic wheals and/or angioedema. First-line testing should include a complete blood count (CBC) with differential, comprehensive metabolic panel (CMP), and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) to rule out underlying infections or inflammatory conditions. While routine allergy testing is often not helpful in CSU, it may be considered in patients with suspected inducible urticaria or concomitant allergic rhinitis/asthma. Second-line investigations, pursued if initial tests are unrevealing or if specific triggers are suspected, can include thyroid function tests, antinuclear antibody (ANA) testing, complement levels (C3, C4), and, in rare cases, skin biopsy. Explore how a stepwise approach to diagnostic testing can improve CSU management. Consider implementing validated patient-reported outcome measures like the Urticaria Activity Score (UAS7) to monitor disease activity and treatment response.
How can I differentiate between chronic inducible urticaria and chronic spontaneous urticaria in my clinical practice, and what specific physical exam findings or diagnostic tests are helpful?+
Distinguishing between chronic inducible urticaria (CIndU) and chronic spontaneous urticaria (CSU) hinges on identifying specific triggers. CIndU presents with wheals and/or angioedema after exposure to identifiable stimuli like pressure, vibration, cold, heat, or sunlight. A detailed patient history is crucial, including questions about activities preceding symptom onset. Physical exam maneuvers, such as applying ice (cold urticaria), rubbing the skin (dermatographism), or applying pressure (delayed pressure urticaria), can be helpful in diagnosing CIndU subtypes. In contrast, CSU occurs without identifiable triggers. Diagnostic testing for CIndU involves specific challenge tests corresponding to suspected subtypes. Learn more about different types of CIndU and appropriate challenge protocols. For CSU, laboratory testing mainly serves to rule out other conditions, as described above.
What are the current evidence-based treatment recommendations for refractory chronic urticaria in adults, especially when first-line H1-antihistamines are insufficient?+
Managing refractory chronic urticaria (CU), where symptoms persist despite up to fourfold dosing of second-generation H1-antihistamines, requires a stepwise approach guided by current guidelines. After maximizing H1-antihistamine doses, adding omalizumab, a monoclonal antibody targeting IgE, is considered the next step. Cyclosporine A, an immunosuppressant, is another second-line option, though it requires careful monitoring for potential adverse effects. For patients unresponsive to these treatments, other options include biologics like dupilumab, other immunosuppressants (e.g., methotrexate, mycophenolate mofetil), or targeted therapies based on individual patient characteristics. Consider implementing shared decision-making to tailor treatment strategies to individual patient needs and preferences. Explore how recent clinical trials are shaping the evolving landscape of refractory CU management.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.